Editor's note: The original version of this story claimed that STARS-ADHD Adjunctive enrolled 2016 subjects, instead of 206. We apologize for this error.
Digital therapeutic company Akili Interactive has announced the first results of an open-label, multisite pediatric ADHD trial providing some patients with the company’s video game-like treatment alongside a stimulant medication.
Called the ...
Following news of hardships at Proteus Digital Health, CEO Andrew Thompson has told STAT News that the company is winding down its high-profile $88 million deal with Otsuka Pharmaceutical, and will be pivoting from its current primary focus on mental disorders toward cancers and infectious disease treatments.
The pharmaceutical company has now acquired the full license for Proteus’ mental health...
Editor's note: This story has been updated with additional statements from Pear Therapeutics.
Pear Therapeutics pulled back the curtain this morning on a number of new deals between the prescription digital therapeutics maker and other tech companies or researchers.
Ranging from virtual reality therapies to voice biomarker tech, the moves appear to be an effort from Pear to add new products to...
SidekickHealth chief executive and cofounder Tryggvi Thorgeirsson; Credit: SidekickHealth
Nordic company SideKickHealth has announced today that it entered a strategic partnership with Bayer to provide a digital medication management and lifestyle change platform to patients with Peripheral Arterial Disease (PAD).
While there is no cure, according to the NHS, lifestyle changes and medicine can help reduce the symptoms of patients with PAD. The condition was estimated to affect over...
A video game-like digital therapy may be key to helping reduce cognitive impairments in adults living with major depressive disorder (MDD).
Results out of a new study conducted by Akili interactive found that patients using the company’s AKL-T03 significantly improved their sustained attention compared to their peers in the control group.
In the study, which was presented at the Meeting of the...
Welldoc is tapping Astellas Pharma to assist Japanese and Asian commercialization efforts for the former’s digital therapeutic for patients with diabetes, the companies announced yesterday.
To kick off the deal, Astellas is making an upfront $15 million payment to Welldoc, which will allow the pharma to jointly develop and commercialize the BlueStar product in the region. The two will also be...
About the author: John Crawford is the founder and managing director of Crawford Works, and an independent consultant with experience in digital health. Until 2018, he was the Healthcare Industry Leader for Europe at IBM, and, from 2016 to 2018, a director of the Global Board of HIMSS, owner of MobiHealthNews. He is now an advisory consultant for HIMSS in Europe. The opinions in this piece are...
This morning Medopad, an artificial intelligence-enabled patient data collection and analytics platform, landed $25 million in Series B funding. The last round was led by pharma giant Bayer’s venture capital branch Leaps by Bayer.
This new announcement brings the UK-based company’s total funding to $50 million, and comes roughly a year and a half after it closed its $28 million Series A round....
Pear Therapeutics has announced a new deal with Ironwood Pharmaceuticals that will explore the platform’s potential for patients with certain gastrointestinal (GI) conditions.
“We are excited to be partnering with Ironwood on this initiative and believe there is a compelling clinical rationale for use of [prescription digital therapeutics] in treating GI diseases,” Dr. Corey McCann, president and...
The past few days have seen new pivotal trial announcements from two startups eyeing FDA submissions for their digital health offerings.
On Thursday Cognoa unveiled an investigation for its pediatric development monitoring and diagnostic tool. This will be a multi-site, prospective, blinded, active comparator study of the tool, which is intended to support primary care autism diagnoses among...
